ESR1 and breast cancer: In summary, our results showed that ER low positive breast cancer presents a substantially better response to NAC than classical ER-positive (ER > 10% positive) breast cancer, and patients with ER low positive have a significantly worse prognosis than those with ER > 10% positive tumors, but a prognosis similar to that of the ER-negative group.